Latest news with #OneMedNet
Associated Press
30-07-2025
- Business
- Associated Press
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, BC / ACCESS Newswire / July 30, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ('Onco' or the 'Company') is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ('Inka Health'), has been selected by OneMedNet Corporation (Nasdaq:ONMD) to lead a high-impact data analytics initiative focused on improving how cancer therapies are brought to market. The project focuses on leveraging OneMedNet's regulatory-grade patient data including Radiology Imaging data to develop external control arms (ECAs), which has the potential to be a faster, more cost-effective alternative to traditional clinical trials. This approach offers a potentially smarter way to generate clinical evidence by leveraging existing patient data, thereby possibly accelerating treatment access and reducing the need for costly, time-consuming trials. The initiative also provides both organizations with exposure to the rapidly expanding Real-World Evidence (RWE) market is projected to exceed $4.6 billion1 globally by 2030. This strategic project reflects growing momentum behind real-world data (RWD) as a critical component of next-generation evidence generation for cancer therapeutics2. OneMedNet's iRWDTM Real-World Data platform and federated provider network offers regulatory-grade, diverse, and longitudinal datasets, making it uniquely suited to drive Real-World Evidence (RWE) studies and accelerate healthcare innovation. The multi-phase project is intended to showcase how OneMedNet's oncology dataset can be used to replicate the results of traditional clinical trials, without the same time, cost, and complexity as traditional trials. By offering a faster and more efficient path to generate the evidence needed for regulatory and reimbursement approvals, this initiative can potentially help accelerate market entry for new cancer therapies, particularly in areas of high unmet needs like colorectal cancer. Inka Health plans to deploy its proprietary SynoGraph platform, which combines machine learning with causal inference methods, to build and validate an ECA for the Keynote-189 trial3 of pembrolizumab in non-small cell lung cancer aligned with regulatory and Health Technology Assessment (HTA) best practices, including those from the FDA, European Medicines Agency (EMA), and National Institute for Health and Care Excellence (NICE). The initial focus will be on non-small cell lung cancer (NSCLC), a prevalent and clinically significant cancer type where real-world insights can meaningfully improve both patient access to therapies and regulatory confidence. We selected Inka Health for this initiative because their methodological approach aligns perfectly with our vision for high-quality evidence generation,' said Aaron Green, President & CEO of OneMedNet. 'Their ability to apply rigorous, AI-driven analytics to our regulatory-grade, diverse datasets makes them the ideal partner to showcase how OneMedNet's Real-World Data can be used as a trusted external control arm in oncology research-with the potential to help pharmaceutical companies realize a stronger ROI on clinical development and driving broader adoption among CROs and life sciences organizations looking for faster, more cost-effective trial alternatives. The collaboration is expected to result in a scientific abstract for submission to ISPOR Europe 2025, reinforcing Inka Health's leadership in applying artificial intelligence and real-world data to oncology research. As ECAs become increasingly prominent in global drug development strategies, this project positions Onco and its subsidiary at the forefront of how industry brings new therapies to patients. 'This collaboration is about more than applying advanced analytics to oncology data. It's about reshaping how we generate credible evidence for regulatory and reimbursement decisions using real-world patients, not just trial participants. With SynoGraph, we're aiming to set a new bar for how external control arms can be built and trusted.' said Paul Arora, Co-Founder of Inka Health. Furthermore, the Company announces, further to its news releases dated May 26, 2025 and March 25, 2025, that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: [email protected]; telephone: +491772481220; and website: ) ('MCS') for the continued provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as research and analytics (the 'Services'). The Services are expected to run until October 30, or until budget exhaustion. The Company has paid MCS EUR 250,000 for the extended term. No securities have been provided to MCS or its principals as compensation. The Services will be executed via digital channels, including Google Ads and native advertising. About OneMedNet OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn't just data, it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities, rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at About Inka Health Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data-including genomics, transcriptomics, and proteomics-SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 [email protected] OneMedNet Contacts: Michael Wong, VP Marketing Email: [email protected] Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's ability to collaborate successfully with OneMedNet, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including, but not limited to, the inability of Inka or the Company to collaborate successfully with OneMedNet. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. 1 Real World Evidence Solutions Market - 2 Wang X, Dormont F, Lorenzato C, et al. Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021. J Cancer Policy. 2023;35:100403. 3 SOURCE: Onco-Innovations Limited press release
Globe and Mail
25-06-2025
- Business
- Globe and Mail
OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress
MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), a leader in AI-powered Real-World Data (RWD) announced today that Aaron Green, President and CEO, issued the following letter to shareholders and other stakeholders of the Company: Dear OneMedNet Shareholders, Partners, and Family, Following a year of significant progress, OneMedNet is navigating 2025 with strong momentum, making substantial strides in expanding our market presence, enhancing our Real-World Data platform, and developing an AI driven tool set to anonymize and De-identify data across multiple industries. My leadership team and I feel it is important that you know our key achievements, including onboarding five major data marketplaces, surpassing 121 million clinical exams in our network, and charting the path forward as we capitalize on the growing demand for de-identified data starting with regulatory-grade RWD. We are excited about OneMedNet's scalable, tech-enabled model that positions us for sustained growth and long-term value creation. 2024 Highlights AI-Powered Platform: Our federated iRWD™ platform leverages cost-effective AI tools to search, de-identify, and curate precise datasets at scale. These tools serve healthcare as well as industries like finance, telecom, and retail through advanced anonymization technology. Expanded Market Reach: We are now partnered with five leading data marketplaces—Amazon Data Exchange (AWS), Protege AI, Bayer Data Marketplace, Datavant, and HealthVerity. These platforms collectively span multiple segments of the healthcare data ecosystem, including real-world evidence, clinical trial optimization, payer-provider data exchange, and AI model training. From AWS's enterprise-scale infrastructure to Datavant and HealthVerity's leadership in de-identified health data, and Protege AI's focus on model-ready datasets, they form a powerful network supporting innovation across life sciences, pharma, and digital health. Network Growth: Our partnerships with over 1,400 hospital and healthcare provider sites have grown our medical imaging-rich RWD repository to over 121 million clinical exams, expanding organically by ~5% annually through daily patient care activities. Amplified Brand Presence: Increased participation in industry trade shows and targeted campaigns has strengthened stakeholder engagement, with imaging's role in longitudinal patient records resonating as a key differentiator. This momentum generated over 130 qualified leads—a threefold increase from previous years—demonstrating rising market interest. The growing demand for these services is further evidenced by many customers consistently returning to OneMedNet first for their data needs, driven by their positive experiences with our platform, quality data and services. Diverse Customer Base: Our healthcare regulatory-grade datasets are licensed by leading life sciences organizations for clinical trials, regulatory submissions, and AI model development, reflecting strong market validation. Regulatory Compliance: Our datasets meet stringent FDA and international standards, enabling real-world evidence (RWE) for submissions, post-market surveillance, and research. AI Innovation: We provide foundational data to train and validate AI models in medical imaging and diagnostics, accelerating advancements in precision medicine. What Sets Us Apart OneMedNet does not just collect raw data. We deliver: AI-assisted de-identification and anonymization, applicable across industries like healthcare, finance, telecom, and retail. OneMedNet delivers premium, purpose-built RWD, not raw data. Curated, regulatory-grade datasets Longitudinal tracking across multiple care events. Imaging-centric iRWD™, enhanced by custom cohort matching and AI-powered refinement. High customer satisfaction, driving repeat orders from leading life sciences organizations. The Opportunity Ahead The need for RWD has never been greater. The traditional model of running lengthy, expensive clinical trials is being disrupted. Regulators like the FDA and European Medicines Agency (EMA) are increasingly encouraging the use of RWE as part of the approval process. According to McKinsey generative AI and RWD could unlock $60 billion to $110 billion in annual value across the pharmaceutical and medical-device sectors. Recent industry analysis projects healthcare data growth at a 36% CAGR through 2030, far outpacing other sectors. OneMedNet is uniquely positioned to capture this multi-billion-dollar opportunity, leveraging our scalable platform, extensive network, and AI-driven capabilities. Subscription-Based pricing model We have added a subscription-based Data License Agreement (DLA) structure to drive Annual Recurring Revenue (ARR). Our platform now supports near real-time data updates, allowing access to curated, regulatory-grade datasets through flexible, recurring licenses. This enhances scalability, strengthens network effects, and aligns with long-term demand for high-quality RWD. Our partner hospitals and clinics share the revenue, incentivizing network expansion and data depth. Looking Forward Our three pillars—Platform, Partners, and People—anchor our strategy. Our proven AI de-identification and anonymization across industries, iRWD™ platform, growing network of provider sites, and experienced leadership team, with expertise in AI, cloud solutions, healthcare, regulatory compliance, and M&A, are aligned for execution. We are intensifying investor outreach and communication to highlight our progress and vision. To our shareholders: Thank you for your support. While stock price fluctuations may not reflect our full potential, we are building enduring value through data, scalability, and relevance to the future of healthcare and beyond. Sincerely, Aaron Green President and CEO OneMedNet Corporation Investor Relations - About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Yahoo
24-06-2025
- Business
- Yahoo
OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities
MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has entered into agreements with accredited investors in private placement transactions at $0.42 per share of common stock that resulted in gross proceeds of approximately $3.7 million, before deducting fees and expenses payable by the Company. Certain Company's founders and directors participated in the private placement transactions. OneMedNet intends to use the proceeds of these private placements for working capital and general corporate purposes. The private placements closed on or about June 19, 2025, and the price per share of common stock sold in these private placements exceeded the minimum price requirement under Nasdaq rules. During the second quarter of 2025, the Company took additional steps to strengthen its balance sheet and enable it to continue its strategy of adding Bitcoin to the balance sheet: Settling approximately $3.26 million of deferred underwriter fees payable to the underwriter in the Company's business combination transaction. Settling approximately $1.08 million additional trade payables and other amounts owed by the Company. Obtaining notices from the Company's noteholders to convert approximately $6.56 million of their principal and interest into Company common stock. Redeeming for cash the remaining $250,000 outstanding under the Company's original convertible promissory note previously issued to Yorkville Advisors Global in June 2024, which contained certain discounted conversion features. As a result of these actions, the Company settled or converted approximately $11.0 million of the Company's current liabilities, representing a 60% reduction in the Company's total liabilities outstanding as of March 31, 2025. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of the securities in the private placement transactions described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. The Company agreed to register the shares issued in these private placements with the SEC. About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. OneMedNet Contacts: Michael Wong, VP of MarketingEmail: SOURCE: ONEMEDNET CORPORATIONSe produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Associated Press
13-05-2025
- Business
- Associated Press
OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the Datavant Connect platform to accelerate healthcare data discovery, analytics, and partner assessment processes. These new advancements will be presented by Datavant this week at ISPOR 2025, highlighting the importance of secure, scalable, and fit-for-purpose data solutions in driving innovation across healthcare and life sciences. The healthcare industry has experienced a tremendous volume of health-related data generation—extending beyond patient interactions to include genomic sequencing, biomarker data, and more. In many ways, data has become the new oil, holding immense value for clinical and scientific advancement. However, like crude oil, this raw data must be refined—its fragmented and siloed nature continues to hinder accessibility and usability. As healthcare and life sciences organizations increasingly seek targeted, fit-for-purpose datasets, scalable and secure technological solutions have become essential to unlocking its full potential. Leveraging AWS Clean Rooms, OneMedNet will offer sophisticated data partner assessment and discovery tools through the Datavant Connect platform, enabling secure collaboration environments without direct data movement or sharing of raw data. This 'no underlying data movement' approach significantly enhances data security and privacy, allowing for effective feasibility analyses between data sources and buyers. These advancements facilitate faster identification and evaluation of relevant healthcare datasets, directly addressing the industry's strategic, privacy, and data handling challenges. By empowering healthcare organizations with precise, secure, and efficient data access, OneMedNet accelerates the generation of valuable insights and transformative outcomes. 'Much of today's healthcare data remains untapped due to complexity and interoperability issues,' continued Aaron Green. 'Datavant Connect powered by AWS Clean Rooms effectively removes these barriers, positioning OneMedNet as an indispensable partner for organizations aiming to fully harness the potential of healthcare data.' About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. OneMedNet Contacts: Michael Wong, VP Marketing Email: [email protected] SOURCE: ONEMEDNET CORPORATION
Yahoo
13-05-2025
- Business
- Yahoo
OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the Datavant Connect platform to accelerate healthcare data discovery, analytics, and partner assessment processes. These new advancements will be presented by Datavant this week at ISPOR 2025, highlighting the importance of secure, scalable, and fit-for-purpose data solutions in driving innovation across healthcare and life sciences. The healthcare industry has experienced a tremendous volume of health-related data generation—extending beyond patient interactions to include genomic sequencing, biomarker data, and more. In many ways, data has become the new oil, holding immense value for clinical and scientific advancement. However, like crude oil, this raw data must be refined—its fragmented and siloed nature continues to hinder accessibility and usability. As healthcare and life sciences organizations increasingly seek targeted, fit-for-purpose datasets, scalable and secure technological solutions have become essential to unlocking its full potential. Leveraging AWS Clean Rooms, OneMedNet will offer sophisticated data partner assessment and discovery tools through the Datavant Connect platform, enabling secure collaboration environments without direct data movement or sharing of raw data. This 'no underlying data movement' approach significantly enhances data security and privacy, allowing for effective feasibility analyses between data sources and buyers. These advancements facilitate faster identification and evaluation of relevant healthcare datasets, directly addressing the industry's strategic, privacy, and data handling challenges. By empowering healthcare organizations with precise, secure, and efficient data access, OneMedNet accelerates the generation of valuable insights and transformative outcomes. "Much of today's healthcare data remains untapped due to complexity and interoperability issues," continued Aaron Green. "Datavant Connect powered by AWS Clean Rooms effectively removes these barriers, positioning OneMedNet as an indispensable partner for organizations aiming to fully harness the potential of healthcare data." About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. OneMedNet Contacts: Michael Wong, VP Marketing Email: SOURCE: ONEMEDNET CORPORATIONError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
